Outside of the USA, click here for more information.
Press Esc to close

A cornstarch with unique properties for the dietary management of hepatic Glycogen Storage Disease (GSD)

About Glycosade


What is glycosade?

Vitaflo® has worked with leading metabolic centers, scientists and individuals with GSD in the development of Glycosade®, a hydrothermally processed high amylopectin cornstarch that can help keep blood sugar levels within the normal reference range for longer compared to uncooked cornstarch.

How do you take your glycogen storage disease?

Glycosade must only be started after consulting with your healthcare professional.

  • Glycosade can be mixed and taken in the same way as uncooked cornstarch (UCCS).
  • Always consult with your doctor or dietitian before making any changes to your diet.

Age Indication

  • Glycosade is suitable for use from 5 years of age in the United States.

Why use Glycosade®?

  • Clinical evaluation comparing Glycosade® to uncooked cornstarch for overnight dietary management of GSD has shown that Glycosade®:
    • Significantly prolongs the duration of normoglycemia to support longer overnight fasting1-3
    • Allows a more gradual decrease of blood glucose levels, reducing the risk of a rapid onset of hypoglycemia1
    • Supports adherence and quality of sleep due to avoidance of a middle-of-the-night dose2-5
    • Supports metabolic control, which is expected to positively impact long-term health outcomes2,3

Glycosade must only be started after consulting with your healthcare provider. Speak to your healthcare provider to learn more about Glycosade and find out if it may be appropriate for you.

Nutrition Information

View full datasheet.

For dosage and administration, please consult your healthcare professional.

 

[1] Correia CE, Bhattacharya K, Lee PJ, et al. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr. 2008;88(5):1271–6.
[2] Ross KM, Brown LM, Corrado MM, et al. Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type 1. J Inherit Metab Dis Rep. 2015; DOI 10.1007/8904_2015_488.
[3] Ross KM, Brown LM, Corrado MM, et al. Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease types 0, III, VI and IX. J Nutr Ther. 2015;4(4):137–42.
[4] Storch E, Keeley M, Merlo L, Jacob M, Correia C, Weinstein D. Psychological Functioning in Youth with Glycogen Storage Disease Type 1. J Pediatr Psychol. 2008;33(7):728–38.
[5] Rousseau-Nepton I, Huot C, Laforte D, et al. Sleep and quality of life of patients with glycogen storage disease on standard and modified uncooked cornstarch. Mol Genet Metab. 2018;123:326–330.